<?xml version="1.0" encoding="UTF-8"?>
<ref id="B29">
 <label>29</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Han</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Cheng</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Zhou</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)</article-title>. 
  <source>Br J Cancer</source> (
  <year>2018</year>) 
  <volume>118</volume>:
  <page-range>654–61</page-range>.  
  <pub-id pub-id-type="doi">10.1038/bjc.2017.478</pub-id>
 </mixed-citation>
</ref>
